Literature DB >> 17464788

Is antipsychotic medication stigmatizing for people with mental illness?

Martha Sajatovic1, Janis H Jenkins.   

Abstract

Antipsychotic medications are clearly identified as important in the treatment of individuals with schizophrenia and with bipolar disorder. However, negative societal reaction related to having a serious mental illness and the socially undesirable side effects associated with antipsychotic medication treatment may combine to worsen stigma associated with treatment for mental illness. Specific stigmatizing effects of antipsychotic therapy may be difficult to evaluate independently from factors such as symptoms, insight into illness and side effects. Attitudes towards antipsychotic medication may be positive in individuals who recognize therapeutic drug effects, however other individuals may view medications negatively due to a sense of stigma. Stigma among individuals with bipolar disorder in relation to treatment with antipsychotic medication has not been well addressed in the literature. An additional concern among individuals with bipolar disorder who receive antipsychotic medications may be the notion that antipsychotics are 'schizophrenia drugs', and thus an inappropriate treatment for their condition. Antipsychotic medications can be stigmatizing for patients with serious mental illness, however the roots of stigma are extensive, and efforts to minimize stigma can only be successful when addressed by the individual with illness, their families and loved ones, treatment providers and society at large.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464788     DOI: 10.1080/09540260701278911

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  17 in total

1.  Internalized stigma and stigma resistance among patients with mental illness in Han Chinese population.

Authors:  Yin-Ju Lien; Yu-Chen Kao; Yia-Ping Liu; Hsin-An Chang; Nian-Sheng Tzeng; Chien-Wen Lu; Ching-Hui Loh
Journal:  Psychiatr Q       Date:  2015-06

2.  Ward features affecting stigma experiences in contemporary psychiatric hospitals: a multilevel study.

Authors:  Mieke Verhaeghe; Piet Bracke
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

3.  The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia.

Authors:  Yin-Ju Lien; Hsin-An Chang; Yu-Chen Kao; Nian-Sheng Tzeng; Chien-Wen Lu; Ching-Hui Loh
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-07-29       Impact factor: 5.270

4.  A trans-diagnostic approach to psychosis, psychiatric medication nomenclature and stigma.

Authors:  Marina Economou; Helen Lazaratou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-01-10       Impact factor: 5.270

Review 5.  Subthreshold bipolarity: diagnostic issues and challenges.

Authors:  Robin Nusslock; Ellen Frank
Journal:  Bipolar Disord       Date:  2011 Nov-Dec       Impact factor: 6.744

Review 6.  Medication nonadherence in bipolar disorder: a narrative review.

Authors:  Ibrahim Jawad; Stuart Watson; Peter M Haddad; Peter S Talbot; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-16

7.  Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Curtis Tatsuoka; Weronika Micula-Gondek; Edna Fuentes-Casiano; Christopher S Bialko; Kristin A Cassidy
Journal:  Bipolar Disord       Date:  2012-05       Impact factor: 6.744

8.  What do you think of us? Evaluating patient knowledge of and satisfaction with a psychiatric outpatient service.

Authors:  F Jabbar; P Casey; S L Schelten; B D Kelly
Journal:  Ir J Med Sci       Date:  2010-05-29       Impact factor: 1.568

9.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

10.  Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole.

Authors:  David J Muzina
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.